IL146144A0 - Method and means for producing high titer, safe, recombinant lentivirus vectors - Google Patents

Method and means for producing high titer, safe, recombinant lentivirus vectors

Info

Publication number
IL146144A0
IL146144A0 IL14614400A IL14614400A IL146144A0 IL 146144 A0 IL146144 A0 IL 146144A0 IL 14614400 A IL14614400 A IL 14614400A IL 14614400 A IL14614400 A IL 14614400A IL 146144 A0 IL146144 A0 IL 146144A0
Authority
IL
Israel
Prior art keywords
safe
recombinant lentivirus
producing high
high titer
lentivirus vectors
Prior art date
Application number
IL14614400A
Other languages
English (en)
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of IL146144A0 publication Critical patent/IL146144A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14614400A 1999-04-29 2000-04-26 Method and means for producing high titer, safe, recombinant lentivirus vectors IL146144A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13167199P 1999-04-29 1999-04-29
PCT/US2000/011097 WO2000066759A1 (en) 1999-04-29 2000-04-26 Method and means for producing high titer, safe, recombinant lentivirus vectors

Publications (1)

Publication Number Publication Date
IL146144A0 true IL146144A0 (en) 2002-07-25

Family

ID=22450511

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14614400A IL146144A0 (en) 1999-04-29 2000-04-26 Method and means for producing high titer, safe, recombinant lentivirus vectors

Country Status (9)

Country Link
US (2) US7250299B1 (de)
EP (2) EP1849873B1 (de)
JP (1) JP4979851B2 (de)
AT (2) ATE528406T1 (de)
AU (1) AU778698B2 (de)
CA (1) CA2370103C (de)
DE (1) DE60035676T2 (de)
IL (1) IL146144A0 (de)
WO (1) WO2000066759A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2003534787A (ja) * 2000-05-26 2003-11-25 カイロン コーポレイション レンチウイルスベクターを使用する神経細胞の形質導入の方法
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
EP1594459B1 (de) 2002-12-30 2010-02-17 Angiotech International Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
WO2009049350A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
WO2013090409A1 (en) * 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
CN104717971A (zh) 2012-06-05 2015-06-17 澳大利亚国立大学 用白介素-4拮抗剂进行疫苗接种
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
NZ711807A (en) 2013-02-06 2020-06-26 Celgene Corp Modified t lymphocytes having improved specificity
HUE053136T2 (hu) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
BR112016004091A2 (pt) * 2013-08-29 2017-10-17 Univ Temple métodos e composições para tratamento guiado por rna de infecção por hiv
ES2813437T3 (es) 2014-07-11 2021-03-23 Celgene Corp Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T
EP3194579A4 (de) 2014-08-12 2018-04-04 Anthrogenesis Corporation Zur aufnahme des b-zellbereichs von lymphknoten, der haut oder des magen-darm-trakts manipulierte car-t-lymphozyten
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
HUE059941T2 (hu) 2016-02-01 2023-01-28 Bioverativ Therapeutics Inc Optimalizált VIII-as faktor gének
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CA3041284A1 (en) 2016-10-20 2018-04-26 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
EP4041873A4 (de) 2019-10-08 2023-10-25 Trustees of Boston College Proteine, die mehrere verschiedene unnatürliche aminosäuren enthalten, und verfahren zum herstellen und verwenden solcher proteine
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN115247190B (zh) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
TW202321278A (zh) 2021-08-06 2023-06-01 美商西建公司 用於選擇性降解工程蛋白質的組合物和方法
CA3229526A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
FR2629469B1 (fr) 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
AU6075190A (en) 1989-06-30 1991-01-17 Regents Of The University Of California, The Retrovirus detection
US5747307A (en) 1992-02-28 1998-05-05 Syngenix Limited Mason-Pfizer Monkey Retroviral packaging defective vectors
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6051427A (en) 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0759471A4 (de) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co Rekombinanter vektor bestehend aus dem menschlichen immunschwäche-virus und verfahren zu seiner herstellung
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1123497A (en) 1995-11-28 1997-06-19 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
US5750383A (en) 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
CA2265522A1 (en) * 1996-09-17 1998-03-26 The Salk Institute For Biological Studies Retroviral vectors capable of transducing non-dividing cells
CZ137399A3 (cs) 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
JP2001510053A (ja) 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
EP1076715B1 (de) * 1998-05-13 2007-07-18 Genetix Pharmaceuticals Inc. Lentivirale Verpackungszellen

Also Published As

Publication number Publication date
EP1171624A4 (de) 2002-06-26
EP1849873A1 (de) 2007-10-31
JP2003508017A (ja) 2003-03-04
CA2370103A1 (en) 2000-11-09
JP4979851B2 (ja) 2012-07-18
EP1849873B1 (de) 2011-10-12
ATE368122T1 (de) 2007-08-15
AU778698B2 (en) 2004-12-16
AU4489700A (en) 2000-11-17
WO2000066759A1 (en) 2000-11-09
DE60035676D1 (de) 2007-09-06
EP1171624A1 (de) 2002-01-16
CA2370103C (en) 2011-08-02
EP1171624B1 (de) 2007-07-25
DE60035676T2 (de) 2008-04-30
US20080241929A1 (en) 2008-10-02
ATE528406T1 (de) 2011-10-15
US8652837B2 (en) 2014-02-18
US7250299B1 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
IL146144A0 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1036182A4 (de) Verfahren und mittel zur herstellung von sicheren, rekombinanten lentivirusvektoren mit hohem titer
GB2369121A (en) Producer cell for the production of retroviral vectors
GB9803351D0 (en) Anti-viral vectors
EP0675198A4 (de) Gene die steriles pflanzencytoplasma identifizieren und verfahren zur herstellung hybrider pflanzen durch verwendung derselben.
EP0629608A3 (de) N-Acyl-N,N',N'-Ethylendiamintriessigsäurederivate und Verfahren zu ihrer Herstellung.
EP0661325A3 (de) Verfahren zur kontinuierlichen Herstellung von Laktidcopolymer.
DE69818077D1 (de) Ein kombinationsverfahren zur herstellung von ethylen, ethylbenzol und styrol
DE58905993D1 (de) Vorrichtung zum Greifen, Auf- und Abstapeln und Fördern von Glastafeln.
ZA875101B (en) Bimodal star-block copolymers,showing excellent optical properties and resilience,and process for their manufacture
EP0668298A4 (de) Maleincopolymer, verfahren zur herstellung und dessen anwendung.
IL181695A0 (en) Methods for cultivating cells and propagating viruses
DE68907447D1 (de) Geblasene, einstueckige flasche und verfahren zur herstellung derselben.
NZ228105A (en) Antihypertensive hyperimmune milk, its production and medicaments therefrom
ES8607018A1 (es) Preparaciones medicinales solidas
HUT59136A (en) Process for producing 3-(pyroglutamyl)-l-thiazolidine-4-carboxylic acid and its derivatives
AU8172394A (en) Thermal treated coal, and process and apparatus for preparing the same
EP0440207A3 (en) Expression of hiv1 and hiv2 polypeptides and use thereof
EP0571549A4 (de) Neuartige integrin spezifität für das hiv-tat-protein.
EP1375502A4 (de) Verfahren zur produktion von 2,6-dihalogenopurinen
EP0537488A3 (en) Artificial standard and control sera, process for their production and use
EP0614971A3 (de) Neuartige Cyclodextrin-glukanotransferase, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von Cyclodexrin mittels dieser.
EP0636611A3 (en) Optically active 1,4-dihydropyridine derivatives and process for preparing the same.
EP0647654A3 (de)
ZA992975B (en) Process for preparing acetaldehyde from ethylene and oxygen.

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired